Micron Technology, Inc., (NASDAQ:MU) on 6 January announced results of operations for its first quarter of fiscal 2015, which ended December 4, 2014. Revenues for the first quarter of fiscal 2015 were $4.57 billion and were 8 percent higher compared to the fourth quarter of fiscal 2014 and 13 percent higher compared to the first quarter of fiscal 2014. Cash flows from operations were $1.59 billion for the first quarter of fiscal 2015.On Monday shares of Micron Technology, Inc. (NASDAQ:MU) closed at $31.66. Company’s sales growth for last 5 years was 27.80% and EPS growth for next 5 years is recorded as 15.00%.
Zacks upgraded shares of Norcraft Companies (NYSE:NCFT) from a neutral rating to an outperform rating in a research report released on Wednesday morning. Zacks currently has $19.60 price objective on the stock. Norcraft Companies, Inc. (NYSE:NCFT) in last trading activity advanced 9.45% to close at $21.32. Company weekly performance is 12.98% while its quarterly performance stands at 36.67%. Norcraft Companies, Inc. (NYSE:NCFT) is 4.66% away from its 52 week high.
MutualFirst Financial (NASDAQ:MFSF) SVP Charles J. Viater sold 1,800 shares of the company’s stock on the open market in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $21.26, for a total value of $38,268.00. Following the sale, the senior vice president now directly owns 123,374 shares of the company’s stock, valued at approximately $2,622,931. On last trading day Mutualfirst Financial Inc. (NASDAQ:MFSF) advanced 0.32% to close at $21.96. Its volatility for the week is 2.27% while volatility for the month is 2.63%. MFSF’s sales growth for past 5 years was -4.50% and its EPS growth for past 5 years was 17.70%. Mutualfirst Financial Inc. (NASDAQ:MFSF) monthly performance is 5.58%.
The Director of Fossil Group Inc, (NASDAQ:FOSL) Shroff Jal S sold 10,000 shares at $106.38 on December 15, 2014. The Insider selling transaction had a total value worth of $1,063,800. Fossil Group, Inc. (NASDAQ:FOSL) has 0.10% insider ownership while its institutional ownership stands at 94.70%. In last trading activity company’s stock closed at $102.82.
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced successful top-line results of a Phase 1b study of LPCN 1107, the company’s oral hydroxyprogesterone caproate (“HPC”) product candidate. The primary objectives of the study were to determine the pharmacokinetics and bioavailability of LPCN 1107 relative to an intramuscular (“IM”) HPC, as well as safety and tolerability in pregnant women.On last trading day Lipocine Inc. (NASDAQ:LPCN) advanced 7.87% to close at $7.13. Its volatility for the week is 9.86% while volatility for the month is 5.91%. Lipocine Inc. (NASDAQ:LPCN) monthly performance is 34.02%.